From MS to NMOSD to early Alzheimer's disease, neurologic mAbs are delivering proven clinical benefit. But as efficacy becomes less of a differentiator, what determines whether these therapies reach patients? In this art...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Operational discipline is a critical determinant of clinical utility for neurologic monoclonal antibodies
In neurologic mAb development, the therapies that reach patients will be those designed not only to work, but to be delivered. Discover how operational discipline is emerging as a key differentiator in translating scientific advances into clinical utility.
-
Clinical success for CNS mAbs depends on more than mechanisms of action alone
The success of CNS monoclonal antibodies (mAbs) depends on more than innovative science. Robust clinical operations and safety governance are critical to protecting patients and advancing development. Discover the key operational considerations for neurologic mAbs in the article.
-
Shifting paradigms of clinical trial design accelerate CNS R&D
Meeting the demand for clinically relevant neurodegenerative treatments requires a paradigm shift in how central nervous system (CNS) clinical trials have been designed and executed. Bill Holt outlines how drug developers are now at the forefront of adopting more nuanced, cost-effective, and patient-centric clinical trial designs.
-
Comment: Realising the full potential of biomarker-informed clinical trials for neurodegenerative disorders
This article by Peter Schueler is based on the recent whitepaper, “Early, precise and efficient; the methods and technologies advancing Alzheimer’s and Parkinson’s R&D”. It explores how the recent approval of amyloid-targeting monoclonal antibodies for Alzheimer’s, following decades of failed trials, can be partially attributed to the development of improved biomarkers for patient screening and outcomes assessment.
-
The role of digital therapeutics in central nervous system clinical trials
In this article, ICON's Louisa Steinberg and Maureen Glynn consider the role of digital therapeutics in the treatment of central nervous system conditions and how they can be used to improve clinical trials.
-
Why pursuit of meaningful Alzheimer’s therapies is gathering pace
In this article in Neuro Rehab Times, ICON expert, Peter Schüler, reflects on the potential implications of new Alzheimer’s therapies on the research landscape.
-
The role of digital health technology tools in supporting medical adherence
In this article in Pharmaceutical Market Europe, Dr Peter Schueler and Dr Isaac R Rodriguez Chavez outline the role of digital health technology tools in supporting medical adherence. 2022 PM Group
-
The growing potential of neurological biomarkers as surrogate endpoints for accelerated drug development
This article by Dr. Peter Schueler explores how digital and liquid biomarkers are developing, and how they can impact the future of neurological studies.
-
-
Alzheimer’s: the search for a cure
An interview in which Peter Schueler discusses the current landscape of Alzheimer’s research and recently published study results.
